Relapsing Remitting Multiple Sclerosis Clinical Trial
Official title:
Clinical Study Protocol: Evaluation of the Efficiency of Ritalin in Multiple Sclerosis Patients
Scientific background:
Growing awareness and accumulating data regarding the cognitive impairment and its
progression in multiple sclerosis (MS) patients has received an important place in
neurological research in the last decade.
Scientific background:
Growing awareness and accumulating data regarding the cognitive impairment and its
progression in multiple sclerosis (MS) patients has received an important place in
neurological research in the last decade. Cognitive impairments occur frequently (43 to 65%)
in MS. Moreover, in up to 50% of patients in whom no cognitive disturbances are found on
routine neurological examination, cognitive impairments can be elicited using sensitive and
disease specific neuropsychological tests. Even in patients with short disease duration of
less than two years, discrete impairment of cognitive function may be found in up to 60% on
neuropsychological testing without impacting activities of daily living.
We have recently reported that cognitive impairment occurred in 53.7% of patients with
probable MS (evaluated within a mean of one month of the onset of new neurological
symptoms). Verbal abilities and attention span were most frequently affected (43.3 and 41.8%
respectively). An additional study demonstrated that MS patients within the first 5 years of
disease onset presented attentional dysfunction only when the cognitive load of the
attention task was high and when controlled information processing was required. This high
rate of attention impairment found in MS patients early in the disease process may have a
significant impact on quality of life and activities of daily living as attention is one of
the most fundamental cognitive functions essential for normal daily activities and a
requisite step towards conscious perception. Consequently, we suggest investigating whether
treatment with Ritalin (methylphenidate) has an effect on patients.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01945359 -
Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design
|
N/A | |
Completed |
NCT01450124 -
Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)
|
Phase 2 | |
Completed |
NCT01456416 -
Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities
|
Phase 4 | |
Recruiting |
NCT05277740 -
Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis
|
||
Completed |
NCT03718247 -
Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS
|
||
Active, not recruiting |
NCT03471338 -
Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme
|
N/A | |
Recruiting |
NCT03004079 -
Clinical Importance of Glucose Regulation in Relapsing MS
|
||
Terminated |
NCT02266121 -
Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT01963611 -
Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)
|
Phase 2 | |
Active, not recruiting |
NCT01464905 -
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
|
Phase 3 | |
Completed |
NCT01225289 -
Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients
|
Phase 4 | |
Recruiting |
NCT00242268 -
A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis
|
Phase 3 | |
Completed |
NCT00203086 -
A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis
|
Phase 4 | |
Completed |
NCT00616187 -
Atorvastatin in Relapsing-Remitting Multiple Sclerosis
|
Phase 2 | |
Recruiting |
NCT06083753 -
Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis
|
Phase 2 | |
Active, not recruiting |
NCT04602390 -
Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
|
Phase 1 | |
Recruiting |
NCT06159712 -
Comparative Study of High-Efficacy Disease Modifying Treatment of Relapsing Multiple Sclerosis
|
N/A | |
Recruiting |
NCT04604041 -
Investigation of Subclinical Markers of Multiple Sclerosis
|
||
Terminated |
NCT03536559 -
Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT02490982 -
Teriflunomide Observational Effectiveness Study
|